Answers are grounded in this paper and cite their sources.
Dear Editor, A rare disease (RD) is expected to affect a small proportion of a population and is defined variably based on country, disease prevalence, and severity.[1] Autosomal recessive congenital ichthyosis (ARCI) is one such clinically and genetically heterogeneous group of RDs, predominantly characterized by abnormal skin scaling, caused by bi-allelic pathogenic variants in any of the 10 genes encoding enzymes crucial for skin barrier formation. With no approved cure for ARCI, patients require lifelong daily management (usually symptomatic), leading to high morbidity, financial burden, and a poor quality of life.[2] Hence, precise molecular characterization becomes indispensable to enable preventive strategies like genetic counseling, carrier-risk screening, and prenatal testing (when required). However, in resource-limited settings like India, access to genetic testing is largely limited by funding, accessibility, disease awareness, and expertise. This is further aggravated by psychosocial distress in terms of anxiety, depression, low self-esteem, and fear of stigmatization among affected individuals.[3] To overcome these challenges, globally, patient support groups (PSGs) are playing a pivotal role in raising public awareness and acting as intermediaries between patients and other stakeholders like government agencies, policymakers, healthcare professionals, and researchers. Herein, we report a 13-year-old male, native of Kommanapalli, a small village in Telangana State, who has been empowered to overcome some of the aforementioned challenges of a burdensome RD due to the cumulative efforts of a national, not-for-profit PSG named the Indian Organization for Rare Diseases (IORD) and the collaborative genomics program (CGP) of a government-funded research institution, that aims to provide equitable access to genome diagnostics in India.[4] The boy was referred to us by IORD, owing to his unusual skin condition that was clinically undiagnosed since the family was unable to visit any recognized medical center due to lack of awareness and poor family income. Once identified, a diagnosis of lamellar ichthyosis (severe subtype of ARCI) was made based on clinical photographs showing generalized dark-brown thick adherent scales with no flexural sparing along with ectropion [Figure 1a]. Interactions with the family also confirmed a history of collodion membrane at birth in the patient, while other family members were apparently healthy.Figure 1: (a) Clinical photograph of our lamellar ichthyosis patient presenting with dark colored scales on the entire body, (b) Pedigree of family (Symbols: half-black = carrier (heterozygous variant); full-black = affected (homozygous variant); open = unaffected (wild-type); open with question mark = sample unavailable; double line = consanguineous marriage and arrow = index patient), (c) Sequence chromatogram depicting the identified variant [TGM1(NM_000359.3):c.748T>G] in homozygous (III.2), heterozygous (I.1, II.1, II.2, and III.1) and wild-type (I.2 and I.3) state in the familyTo confirm the diagnosis, after obtaining informed consent, IORD coordinated collection of blood samples and patient details, while we helped with the genetic evaluation utilizing whole exome sequencing, as described previously.[5] Variant analysis and prioritization based on our in-house bioinformatics pipeline, revealed the presence of a previously reported[6] homozygous ‘likely-pathogenic’ missense variant in TGM1 gene (NM_000359.3:exon4: c.748T>G;p.Trp250Gly). The variant was predicted to be deleterious by multiple pathogenicity-assigning bioinformatics tools and was absent in all publicly available population databases, including the Indian population. Further, the variant validation and familial segregation analysis performed using Sanger sequencing confirmed the autosomal recessive inheritance [Figure 1]. Subsequently, the patient and his family were referred for genetic counseling and the patient was assisted with medical care involving use of emollients and acitretin 25 mg/day, based on recommended guidelines, through a local dermatologist.[7] Through this report, we emphasize the vital role of PSGs like IORD, in initiating active patient participation in decision-making when there is a lack of knowledge and funding limitations in a family dealing with a RD patient. We also highlight the significance of collaborative endeavors in framing a coordinated patient-centric approach to preventing and managing RDs. The burden of RDs, like ARCI in India, is presumably high due to the dense population and widely accepted practices of endogamy and consanguineous marriages. Given the variable access to referral pathways for genetic testing, most definitively diagnosed ARCI patients are usually reported by tertiary hospitals, leaving a large section of affected individuals unrecognized, particularly in rural areas. Further, the lack of prevalence statistics, limited long-term patient follow-up studies, and the overall exclusion of genodermatoses from the National Policy of Rare Diseases (NPRD) impede prioritization of ARCI for prevention or therapeutic development. Since a single clinician or scientist in isolation cannot overcome these challenges, adopting a nationally networked approach becomes relevant in addressing the unmet needs. As ichthyosis-specific PSGs are currently non-existent in the country, the umbrella PSGs [Table 1][4] can aid in raising public awareness, educating and assisting patients, and promoting disease prevention strategies for RDs like ARCI. However, CGP supported by government-funded institutions, can help in making precise genetic diagnosis, thereby facilitating the implementation of such strategies. Overall, we believe that the reach, community connections, and grassroots linkages of PSGs, along with the technical expertise and infrastructural support of CGP, can enable equitable access to diagnostic and therapeutic avenues for RD patients across India.Table 1: A list of umbrella organizations and support groups dedicated towards improving the quality of life for patients with rare diseases in India [adapted from GUaRDIAN Consortium; Sivasubbu S, Scaria V. Genomics of rare genetic diseases-experiences from India. Hum Genomics. 2019;14(1):52.][ 4 ]Declaration of patient consent The authors certify that they have obtained all appropriate parent consent forms. In the form, a parent has given their consent for the patient’s images and other clinical information to be reported in the journal. The parent understands that his name and initial will not be published and due efforts will be made to conceal his identity, but anonymity cannot be guaranteed. Financial support and sponsorship ST acknowledges fellowship support from the Council of Scientific and Industrial Research (CSIR; Ref no: GATE31/0043(13267)/2022-EMR-I); VKY acknowledges funding support (Ref. No: OLP1164) from Council of Scientific and Industrial Research (CSIR), India. Conflicts of interest There are no conflicts of interest. Use of artificial intelligence (AI) The authors affirm that no generative artificial intelligence (AI) tools or technologies were used in the writing, data analysis, image generation, or any other aspect of the preparation of this manuscript.
No takes yet. Share an insight, caveat, or question.
Ramaiah et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: